keyword
MENU ▼
Read by QxMD icon Read
search

Chronic GVHD

keyword
https://www.readbyqxmd.com/read/29773281/-cutaneous-and-systemic-t-cell-lymphoma-treated-with-haploidentical-bone-marrow-transplantation
#1
M Méchineaud, M Mercier, Y Le Corre, A Croué, N Ifrah, L Martin
BACKGROUND: Herein, we report a case of systemic cutaneous T-cell lymphoma refractory to standard therapy, the course of which resulted in haplo-identical bone marrow grafting. PATIENTS AND METHODS: A 53-year-old woman consulted for facial erythema with infiltration, keratotic lesions on the trunk, and adenopathies measuring around 1cm on the axilla and inguinal folds. A diagnosis was made of Sézary syndrome (SS), a leukaemic form of epidermotropic cutaneous T-cell lymphoma...
May 14, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29763694/corneal-fluorescein-staining-and-ocular-symptoms-but-not-schirmer-test-are-useful-as-indicators-of-response-to-treatment-in-chronic-ocular-gvhd
#2
Francisco Amparo, Hasanain Shikari, Ujwala Saboo, Reza Dana
PURPOSE: To evaluate long-term ocular surface clinical signs and symptoms response to therapy in patients with chronic ocular GVHD. METHODS: Retrospective review and data modeling. We reviewed the records of post-bone marrow transplantation patients who were newly diagnosed with ocular GVHD and initiated therapy, and analyzed changes in symptoms (Ocular Surface Disease Index [OSDI]; Symptom Assessment in Dry Eye [SANDE]) and signs (corneal fluorescein staining [CFS]; Schirmer test)...
May 12, 2018: Ocular Surface
https://www.readbyqxmd.com/read/29760162/unrelated-cord-blood-transplantation-in-patients-with-acquired-refractory-aplastic-anemia-a-nationwide-phase-ii-study
#3
Regis Peffault de Latour, Sylvie Chevret, Charlotte Jubert, Anne Sirvent, Claire Galambrun, Annalisa Ruggeri, Virginie Gandemer, Jérôme Cornillon, Fanny Rialland, Jean-Hugues H Dalle, Edouard Forcade, Benedicte Bruno, Catherine Paillard, Pierre S Rorlich, Alexandra Salmon, Sabine Fürst, Flore Sicre de Fontbrune, Marie Therese Rubio, Jacques-Olivier Bay, Mohamad Mohty, Jerome Larghero, Eliane Gluckman, Gerard Socié
Outcomes remain poor for patients with refractory severe aplastic anemia (SAA). Alternative donor transplantation may be considered, but results from previous studies have not been encouraging. We conducted a prospective nationwide phase II study to assess the efficacy and safety of unrelated cord blood transplantation (CBT) in patients with refractory SAA (APCORD protocol, NCT 01343953). To demonstrate a significant difference in one-year survival from 20% (null hypothesis) to 50% (alternative hypothesis), we needed to include 25 transplanted patients...
May 14, 2018: Blood
https://www.readbyqxmd.com/read/29755481/-phage-transplantation-in-allotransplantation-possible-treatment-in-graft-versus-host-disease
#4
Andrzej Górski, Ewa Jończyk-Matysiak, Ryszard Międzybrodzki, Beata Weber-Dąbrowska, Jan Borysowski
Graft-versus-host disease, both acute and chronic (aGvHD, cGvHD) remains a major complication in patients undergoing hematopoietic cell transplantation (HCT) and a significant therapeutic challenge, as many patients do not respond adequately to presently available therapy. Increasing antimicrobial resistance has greatly revived interest in using bacterial viruses (phages) to combat antibiotic-resistant bacteria. In recent years, evidence has accumulated indicating that phages also have anti-inflammatory and immunomodulatory activities...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29753158/melphalan-based-reduced-intensity-conditioning-is-associated-with-favorable-disease-control-and-acceptable-toxicities-in-patients-older-than-70-with-hematologic-malignancies-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#5
Monzr M Al Malki, Nitya Nathwani, Dongyun Yang, Saro Armenian, Sanjeet Dadwal, Jaroslava Salman, Sally Mokhtari, Thai Cao, Karamjeet Sandhu, Michelle Rouse, Matthew Mei, Haris Ali, Pablo Parker, Joseph Alvarnas, Eileen Smith, Margaret O Donnell, Guido Marcucci, David Snyder, Auayporn Nademanee, Stephen J Forman, Anthony Stein, Ryotaro Nakamura
Allogeneic hematopoietic stem cell transplantation (AlloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study, we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent AlloHCT with melphalan (Mel)-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was prompt, with median time to neutrophil engraftment of 15 days...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753157/treosulfan-fludarabine-and-low-dose-total-body-irradiation-for-children-and-young-adults-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome-undergoing-allogeneic-hematopoietic-cell-transplantation-a-prospective-phase-ii-trial-of-the-pediatric-blood-and
#6
Eneida R Nemecek, Ralf A Hilger, Alexia Adams, Bronwen E Shaw, Deidre Kiefer, Jennifer Le-Rademacher, John E Levine, Gregory Yanik, Wing Leung, Julie-An Talano, Paul Haut, David Delgado, Neena Kapoor, Aleksandra Petrovic, Roberta Adams, Rabi Hanna, Hemalatha Rangarajan, Jignesh Dalal, Joseph Chewning, Michael R Verneris, Stacy Epstein, Lauri Burroughs, Evelio D Perez-Albuerne, Michael A Pulsipher, Colleen Delaney
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (1-19) underwent allogeneic HCT for AML in first (n=18), second (n=11), third or greater remission (n=3); or MDS (n=8) using bone marrow (n=25), peripheral blood stem cells (n=5) or cord blood (n=9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m2 /day (BSA ≤ 0...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29747286/-anti-cd-25-monoclonal-antibody-as-a-salvage-therapy-for-steroid-refractory-acute-graft-versus-host-disease-in-80-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation
#7
T Tao, S L Xue, F Chen, Y Xu, X Ma, M Miao, X W Tang, D P Wu
Objective: To investigate the efficacy of anti-CD(25) monoclonal antibody for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Methods: A total of 80 patients with SR-aGVHD from January 1st 2012 to December 31st 20l6 were enrolled in this study. Acute GVHD were classified as classic aGVHD ( n= 72) and late-onset aGVHD ( n= 8). Anti-CD(25) monoclonal antibodys (mAb) were administrated on days 1, 4, 8, 15, and 22. The efficacy of anti-CD(25) mAb was evaluated at day 28 after the initial treatment...
May 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29745014/posttransplant-cyclophosphamide-for-haploidentical-stem-cell-transplantation-in-children-with-wiskott-aldrich-syndrome
#8
Yan Yue, Xiaodong Shi, Zeliang Song, Jiayue Qin, Junhui Li, Shunqiao Feng, Rong Liu
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is the curative treatment for Wiskott-Aldrich syndrome (WAS). However, it is difficult to find a matched donor for patients. Therefore, haploidentical donors should be considered for patients lacking a suitable donor. Our pilot study evaluated whether HSCT with posttransplantation cyclophosphamide (PTCy) is an effective treatment for WAS. METHODS: Haploidentical family donors were selected as donor sources for a total of five patients without a suitable donor between March 2015 and March 2017...
May 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29740177/longitudinal-follow-up-of-response-status-and-concomitant-immunosuppression-in-patients-treated-with-extracorporeal-photopheresis-for-chronic-graft-versus-host-disease
#9
Marietta Nygaard, Tonny Karlsmark, Niels Smedegaard Andersen, Ida Marie Schjødt, Søren Lykke Petersen, Lone Smidstrup Friis, Brian Thomas Kornblit, Henrik Sengeløv
Improvement in chronic graft vs. host disease (cGvHD) following treatment with extracorporeal photopheresis (ECP) has been shown previously. However, the effect is often measured at only one point in time or as best response. Chronic GvHD activity fluctuates over time, so we retrospectively evaluated cGvHD responses in 54 patients with primarily moderate or severe cGvHD throughout the ECP treatment course and after stopping ECP. The dominant response was partial remission (PR) in 33 patients, no change (NC) in 10 patients, progressive disease (PD) in 10 patients and complete remission (CR) in one patient...
May 8, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29739773/graft-versus-host-disease-in-recipients-of-male-unrelated-donor-compared-with-parous-female-sibling-donor-transplants
#10
Anita J Kumar, Soyoung Kim, Michael T Hemmer, Mukta Arora, Stephen R Spellman, Joseph A Pidala, Daniel R Couriel, Amin M Alousi, Mahmoud D Aljurf, Jean-Yves Cahn, Mitchell S Cairo, Corey S Cutler, Shatha Farhan, Usama Gergis, Gregory A Hale, Shahrukh K Hashmi, Yoshihiro Inamoto, Rammurti T Kamble, Mohamed A Kharfan-Dabaja, Margaret L MacMillan, David I Marks, Hideki Nakasone, Maxim Norkin, Muna Qayed, Olle Ringden, Harry C Schouten, Kirk R Schultz, Melhem M Solh, Takanori Teshima, Alvaro Urbano-Ispizua, Leo F Verdonck, Robert Peter Gale, Betty K Hamilton, Navneet S Majhail, Alison W Loren
Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors...
May 8, 2018: Blood Advances
https://www.readbyqxmd.com/read/29728701/ibrutinib-for-bridging-to-allogeneic-hematopoietic-cell-transplantation-in-patients-with-chronic-lymphocytic-leukemia-or-mantle-cell-lymphoma-a-study-by-the-ebmt-chronic-malignancies-and-lymphoma-working-parties
#11
Peter Dreger, Mauricette Michallet, Paul Bosman, Sascha Dietrich, Mohamad Sobh, Ariane Boumendil, Arnon Nagler, Christof Scheid, Jan Cornelissen, Dietger Niederwieser, Lutz Müller, Elizabeth Vandenberghe, Ilaria Scortechini, Helene Schoemans, Niels S Andersen, Jürgen Finke, Domenico Russo, Per Ljungman, Jakob Passweg, Michel van Gelder, Nadira Durakovic, Helene Labussiere-Wallet, Tobias Berg, Gerald Wulf, Wolfgang Bethge, Donald Bunjes, Stefan Stilgenbauer, Maria Elisa Canepari, Michel Schaap, Christopher P Fox, Nicolaus Kröger, Silvia Montoto, Johannes Schetelig
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients...
May 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29726580/hla-drb3-4-5-mismatches-are-associated-with-increased-risk-of-acute-gvhd-in-10-10-matched-unrelated-donor-hematopoietic-cell-transplantation
#12
Stéphanie Ducreux, Valérie Dubois, Kahina Amokrane, Ibrahim Yakoub-Agha, Myriam Labalette, Mauricette Michallet, Marie-Thérèse Rubio, Anne Kennel, Edouard Forcade, Xavier Lafarge, Claude-Eric Bulabois, Dominique Masson, Etienne Daguindau, Anne Devys, Virginie Moalic, Erwann Quelvennec, Abdelali Boudifa, Christophe Picard, Peter Van Endert, Muriel de Matteis, Florent Delbos, Matthieu Filloux, Béatrice Pedron, Virginie Renac, Françoise Hau, Julie Bonneau, Anne Parissiadis, Marylise Fort, Anne Dormoy, Natacha Maillard, Isabelle Jollet, Patrice Chevallier, Anne Cesbron, Jacques-Olivier Bay, Fabienne Quainon, Federico Garnier, Gérard Socié, Pascale Loiseau, Raphaël Porcher, Régis Peffault de Latour
Matching for HLA-A, -B, -C, and -DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe, patients are also matched at the HLA-DQB1 loci (10/10 match). However, there is increasing evidence that matching at HLA-DRB3/4/5 loci may help to lower transplant-related morbidity and mortality. We therefore investigated the impact of HLA-DRB3/4/5 mismatches on outcomes in 1975 patients who received a first 10/10 matched unrelated donor (MUD) HCT in France from 2000 to 2012 for a hematological malignancy...
May 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29726078/unrelated-and-related-donor-transplantation-for-beta-thalassemia-major-a-single-center-experience-from-india
#13
M Joseph John, Amrith Mathew, Chepsy C Philip, Sohan Singh, Tanuja Tanuja, Naveen Kakkar
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment in patients with β-thalassemia major. A matched sibling or a related donor is usually found in only 25%-30% of the patients. There are limited data on matched unrelated donor (MUD) transplants from India. We reviewed HSCT outcome in 56 children with TM who underwent 57 transplants at our center. Related donor (RD) (n=43) and MUD (n=14) transplants were performed with TreoFluT-based conditioning regimen in majority (95%) of patients...
May 3, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29721346/hsct-gave-as-a-manifestation-of-chronic-graft-versus-host-disease-a-case-report-and-review-of-the-existing-literature
#14
Michael J Grant, Mitchell E Horwitz
Gastric antral vascular ectasia or "watermelon stomach" is a significant cause of nonvariceal upper GI bleeding and is characterized by red, tortuous ectatic vessels along longitudinal folds in the gastric antrum. The existing literature links GAVE to patients with cirrhosis, scleroderma, bone marrow transplantation, and chronic renal failure among other associations, but its pathophysiology remains ill-defined. Over 30 cases of hematopoietic stem cell transplant-related GAVE (HSCT-GAVE) have been reported in the literature to date and there are likely many more that go undiagnosed or are attributed to another cause of upper gastrointestinal bleeding...
2018: Case Reports in Transplantation
https://www.readbyqxmd.com/read/29719098/allogeneic-hematopoietic-cell-transplant-following-crizotinib-monotherapy-for-relapsed-refractory-anaplastic-large-cell-lymphoma
#15
Tami D John, Swati Naik, Kathryn Leung, Ghadir Sasa, Caridad Martinez, Robert A Krance
Relapsed ALK-positive ALCL often is responsive to CRZ monotherapy. The subsequent role of allogeneic HCT after achieving second remission is poorly understood. We report 6 children who underwent allogeneic HCT for relapsed ALCL after CRZ. Age at transplant ranged from 10.7 to 22.6 years. Follow-up ranged from 0.9 to 4.5 years. All patients engrafted. Three of 4 patients that received a reduced-toxicity conditioning regimen containing fludarabine, alemtuzumab, and low-dose irradiation showed progressive mixed chimerism...
May 2, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29716416/allogeneic-transplantation-for-relapsed-and-refractory-hodgkin-lymphoma-long-term-outcomes-and-graft-versus-host-disease-free-relapse-free-survival
#16
Francesco Spina, Tommaso Radice, Chiara De Philippis, Martina Soldarini, Maria Chiara Di Chio, Anna Dodero, Anna Guidetti, Simonetta Viviani, Paolo Corradini
This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18-60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%)...
May 1, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29713245/allogeneic-stem-cell-transplantation-for-multiple-myeloma-a-systematic-review-and-meta-analysis-from-2007-to-2017
#17
Xuejiao Yin, Liang Tang, Fengjuan Fan, Qinyue Jiang, Chunyan Sun, Yu Hu
Background: Despite recent advances, multiple myeloma (MM) remains incurable. However, the appearance of allogeneic stem cell transplantation (allo-SCT) through graft-versus-myeloma effect provides a potential way to cure MM to some degree. This systematic review aimed to evaluate the outcome of patients receiving allo-SCT and identified a series of prognostic factors that may affect the outcome of allo-SCT. Patients/methods: We systematically searched PubMed, Embase, and the Cochrane Library from 2007...
2018: Cancer Cell International
https://www.readbyqxmd.com/read/29707776/epitope-spread-in-chronic-mucosal-gvhd-mucous-membrane-pemphigoid-resolution-with-rituximab
#18
Sara B Huff, Sumithira Vasu, Benjamin H Kaffenberger
No abstract text is available yet for this article.
April 29, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/29705733/novel-management-of-vaginal-chronic-graft-versus-host-disease-causing-haematometra-and-haematocolpos
#19
Alice Buchan, Melissa A Merideth, Richard W Childs, Pamela Stratton
Genital chronic graft-versus-host disease (GVHD) in women posthaematopoietic cell transplantation may cause vaginal mucosal sclerosis. Human papillomavirus (HPV) reactivation, also common post-transplantation, limits local immunosuppressive, but not oestrogen treatment. A 36-year-old nulliparous woman developed coincidental genital chronic GVHD and HPV 22 months after transplant for aplastic anaemia. Topical immunosuppression for GVHD led to an eruption of warts successfully treated with laser surgery and cone biopsy...
April 28, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29703966/cd3-graft-cell-count-influence-on-chronic-gvhd-in-haploidentical-allogeneic-transplantation-using-post-transplant-cyclophosphamide
#20
A Mussetti, C De Philippis, C Carniti, M Bastos-Oreiro, J Gayoso, N Cieri, M Pennisi, F Ciceri, R Greco, J Peccatori, F Patriarca, J Mariotti, L Castagna, P Corradini
The effects of graft or donor characteristics in haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PT-Cy) are largely unknown. In this multicenter retrospective study we analyzed the correlations between graft cell composition (CD34+, CD3+) and donor features on transplant outcomes in 234 patients who underwent HCT between 2010 and 2016. On multivariate analysis, the use of peripheral blood stem cells (PBSC) was associated with an increased incidence of grade 2-4 acute GVHD [HR 1...
April 27, 2018: Bone Marrow Transplantation
keyword
keyword
59454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"